General Information
Drug ID
DR01330
Drug Name
Clofarabine
Synonyms
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048; CAFdA; CFB; Cl-F-Ara-A; Clofarabina; Clofarabine (USAN/INN); Clofarabine [USAN]; Clofarabinum; Clofarex; Clolar; Clolar (TN); Clolar, Evoltra, Clofarabine; Evoltra; Evoltra (TN)
Drug Type
Small molecular drug
Indication Acute lymphoblastic leukemia [ICD11: 2B33.0] Approved [1]
Juvenile myelomonocytic leukemia [ICD11: 2A42] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C10H11ClFN5O3
Canonical SMILES
C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N
InChI
InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
InChIKey
WDDPHFBMKLOVOX-AYQXTPAHSA-N
CAS Number
CAS 123318-82-1
Pharmaceutical Properties Molecular Weight 303.68 Topological Polar Surface Area 119
Heavy Atom Count 20 Rotatable Bond Count 2
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 8
XLogP
0.9
PubChem CID
119182
PubChem SID
8149071 , 10238376 , 10317422 , 12014412 , 14800615 , 14800616 , 29300120 , 46504968 , 47205855 , 50027432 , 56459308 , 57339361 , 71821361 , 77716344 , 81092867 , 92309003 , 92719465 , 93608050 , 99437031 , 99444025 , 103707445 , 104407717 , 109610765 , 118048878 , 124757091 , 125163895 , 126584329 , 126620778 , 126652234 , 126671067 , 129564367 , 134223319 , 134338128 , 135073562 , 135698306 , 136920392 , 136946661 , 136949087 , 137005624 , 141857409 , 143493352 , 144115841 , 144205735 , 152058774 , 152237732 , 152258941 , 160647786 , 160963976 , 162011506 , 162176704
ChEBI ID
CHEBI:681569
TTD Drug ID
D0R5RR
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
CNT3 Transporter Info Concentrative Na(+)-nucleoside cotransporter 3 Substrate [3]
ENT1 Transporter Info Equilibrative nucleoside transporter 1 Substrate [3]
ENT2 Transporter Info Equilibrative nucleoside transporter 2 Substrate [3]
References
1 Clofarabine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
3 Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.